US Greenlights First GLP-1 Tablet for Weight Management
Novo Nordisk, the Danish pharmaceutical company, announced Monday that the US Food and Drug Administration (FDA) has given the go-ahead for its well-known GLP-1 anti-obesity medication, Wegovy, to be available as a pill for weight management.
Mike Doustdar, president and CEO of Novo Nordisk, stated that with the FDA's approval of the Wegovy pill, individuals now have access to a convenient, once-daily oral medication. This pill can help them achieve similar weight loss results as the original Wegovy injection.
While the FDA had previously approved a pill for diabetes treatment, this latest development broadens the treatment's availability. Doctors can now prescribe it for weight loss in adult patients who are obese or overweight and have at least one comorbidity linked to their weight, such as a heart ailment, according to the company.
The US Obesity Care Advocacy Network (OCAN), a non-profit advocacy organization supporting adults facing obesity, expressed its support for the news.
According to the group's statement to AFP, this advancement presents a significant opportunity for individuals managing obesity. It offers an alternative for those who may be hesitant to start injectable treatments and potentially offers a more affordable option.
The US Centers for Disease Control and Prevention (CDC) estimates that approximately 40 percent of American adults are affected by obesity.
A Significant Advancement
The popularity of the new class of appetite-suppressing drugs using GLP-1 agonists, including brands like Ozempic, Wegovy, and Mounjaro, has surged in recent years, largely due to their effectiveness in aiding weight loss. Health tracking apps like Shotlee can help monitor progress and adherence to treatment plans.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Last month, US President Donald Trump announced agreements with both Novo Nordisk and Eli Lilly aimed at reducing the prices of some weight-loss medications. This was negotiated in exchange for tariff certainty.
Trump informed reporters that this is a victory for American patients, with the potential to save lives and enhance the health of millions.
These medications, which can cost US residents over $1,000 monthly, could offer starting oral dosages for as little as $150 under the agreement. However, injectable prices would be higher.
Novo Nordisk's announcement did not provide details on the Wegovy pill's price. However, they mentioned plans to launch the drug in the US in January.
Trump has been actively pursuing drug pricing reforms, reviving efforts from his previous presidential term. Since returning to the White House, he has taken action to encourage pharmaceutical companies to voluntarily lower their prices.
He had previously threatened to impose tariffs of 100 percent on branded pharmaceuticals unless companies established their manufacturing facilities within the United States.
